<code id='1AEB81BEDA'></code><style id='1AEB81BEDA'></style>
    • <acronym id='1AEB81BEDA'></acronym>
      <center id='1AEB81BEDA'><center id='1AEB81BEDA'><tfoot id='1AEB81BEDA'></tfoot></center><abbr id='1AEB81BEDA'><dir id='1AEB81BEDA'><tfoot id='1AEB81BEDA'></tfoot><noframes id='1AEB81BEDA'>

    • <optgroup id='1AEB81BEDA'><strike id='1AEB81BEDA'><sup id='1AEB81BEDA'></sup></strike><code id='1AEB81BEDA'></code></optgroup>
        1. <b id='1AEB81BEDA'><label id='1AEB81BEDA'><select id='1AEB81BEDA'><dt id='1AEB81BEDA'><span id='1AEB81BEDA'></span></dt></select></label></b><u id='1AEB81BEDA'></u>
          <i id='1AEB81BEDA'><strike id='1AEB81BEDA'><tt id='1AEB81BEDA'><pre id='1AEB81BEDA'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge